JP2023528039A5 - - Google Patents
Info
- Publication number
- JP2023528039A5 JP2023528039A5 JP2022573508A JP2022573508A JP2023528039A5 JP 2023528039 A5 JP2023528039 A5 JP 2023528039A5 JP 2022573508 A JP2022573508 A JP 2022573508A JP 2022573508 A JP2022573508 A JP 2022573508A JP 2023528039 A5 JP2023528039 A5 JP 2023528039A5
- Authority
- JP
- Japan
- Prior art keywords
- target rna
- modified
- domain
- polynucleotide
- polynucleotide according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063029996P | 2020-05-26 | 2020-05-26 | |
| US63/029,996 | 2020-05-26 | ||
| US202063112488P | 2020-11-11 | 2020-11-11 | |
| US63/112,488 | 2020-11-11 | ||
| US202063119902P | 2020-12-01 | 2020-12-01 | |
| US63/119,902 | 2020-12-01 | ||
| US202163178056P | 2021-04-22 | 2021-04-22 | |
| US63/178,056 | 2021-04-22 | ||
| PCT/US2021/034301 WO2021242889A1 (en) | 2020-05-26 | 2021-05-26 | Engineered circular polynucleotides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023528039A JP2023528039A (ja) | 2023-07-03 |
| JP2023528039A5 true JP2023528039A5 (https=) | 2024-05-09 |
Family
ID=76523478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022573508A Pending JP2023528039A (ja) | 2020-05-26 | 2021-05-26 | 改変環状ポリヌクレオチド |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20230174977A1 (https=) |
| EP (1) | EP4158017A1 (https=) |
| JP (1) | JP2023528039A (https=) |
| WO (1) | WO2021242889A1 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017220751A1 (en) | 2016-06-22 | 2017-12-28 | Proqr Therapeutics Ii B.V. | Single-stranded rna-editing oligonucleotides |
| CN110352244B (zh) | 2016-09-01 | 2023-03-21 | ProQR治疗上市公司Ⅱ | 化学修饰的编辑rna的单链寡核苷酸 |
| GB201808146D0 (en) | 2018-05-18 | 2018-07-11 | Proqr Therapeutics Ii Bv | Stereospecific Linkages in RNA Editing Oligonucleotides |
| EP3997229A4 (en) * | 2019-07-12 | 2024-07-03 | Peking University | TARGETED RNA EDITING BY HARNESSING ENDOGENOUS ADAR USING MODIFIED RNA |
| WO2021113264A1 (en) * | 2019-12-02 | 2021-06-10 | The Regents Of The University Of California | Engineering circular guide rnas |
| AU2020395113A1 (en) | 2019-12-02 | 2022-06-09 | Shape Therapeutics Inc. | Therapeutic editing |
| JP2024504608A (ja) * | 2021-01-12 | 2024-02-01 | 北京大学 | 遺伝子操作ｒｎａを使用した内因性ａｄａｒの活用による標的化ｒｎａの編集 |
| EP4479535A1 (en) | 2022-02-14 | 2024-12-25 | ProQR Therapeutics II B.V. | Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia |
| JP2025524566A (ja) | 2022-07-15 | 2025-07-30 | プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ | Ａｄａｒ媒介ｒｎａ編集のためのオリゴヌクレオチドおよびその使用 |
| US20260027237A1 (en) | 2022-07-15 | 2026-01-29 | Proqr Therapeutics Ii B.V. | Chemically modified oligonucleotides for adar-mediated rna editing |
| GB202215614D0 (en) | 2022-10-21 | 2022-12-07 | Proqr Therapeutics Ii Bv | Heteroduplex rna editing oligonucleotide complexes |
| WO2024110565A1 (en) | 2022-11-24 | 2024-05-30 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis |
| GB202218090D0 (en) | 2022-12-01 | 2023-01-18 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency |
| AU2023390632A1 (en) | 2022-12-09 | 2025-07-10 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of cardiovascular disease |
| GB202300865D0 (en) | 2023-01-20 | 2023-03-08 | Proqr Therapeutics Ii Bv | Delivery of oligonucleotides |
| WO2024175550A1 (en) | 2023-02-20 | 2024-08-29 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease |
| EP4689110A1 (en) | 2023-03-24 | 2026-02-11 | ProQR Therapeutics II B.V. | Antisense oligonucleotides for the treatment of neurological disorders |
| GB202304363D0 (en) | 2023-03-24 | 2023-05-10 | Proqr Therapeutics Ii Bv | Chemically modified antisense oligonucleotides for use in RNA editing |
| EP4688143A1 (en) | 2023-03-27 | 2026-02-11 | ProQR Therapeutics II B.V. | Antisense oligonucleotides for the treatment of liver disease |
| WO2024235293A1 (zh) * | 2023-05-17 | 2024-11-21 | 中国科学院遗传与发育生物学研究所 | 基于环状rna的引导编辑系统 |
| TW202516003A (zh) | 2023-06-16 | 2025-04-16 | 荷蘭商Ｐｒｏｑｒ治療上市公司Ｉｉ | 用於治療神經退化性疾病之反義寡核苷酸 |
| WO2025051946A1 (en) | 2023-09-07 | 2025-03-13 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of metabolic disorders |
| WO2025104239A1 (en) | 2023-11-16 | 2025-05-22 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of classic galactosemia |
| WO2025132708A1 (en) | 2023-12-20 | 2025-06-26 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of huntington's disease |
| WO2025137637A2 (en) * | 2023-12-21 | 2025-06-26 | Shape Therapeutics Inc. | Wobble base pairs for improving specificity of rna editing |
| WO2025207635A1 (en) * | 2024-03-25 | 2025-10-02 | University Of Wyoming | Compositions and methods for stabilizing a biological material or biologically-derived material |
| GB202404661D0 (en) | 2024-04-02 | 2024-05-15 | Proqr Therapeutics Ii Bv | Antisense oligoncleotides for the treatment of liver disease |
| WO2025224230A1 (en) | 2024-04-25 | 2025-10-30 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of fatty liver disease |
| GB202410081D0 (en) | 2024-07-11 | 2024-08-28 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of cardiovascular disease |
| WO2026022136A1 (en) | 2024-07-23 | 2026-01-29 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of metabolic disorders |
| WO2026060374A2 (en) | 2024-09-16 | 2026-03-19 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of neurological disorders |
| WO2026068781A1 (en) | 2024-09-30 | 2026-04-02 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of liver disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2925866T3 (en) * | 2012-11-30 | 2018-10-29 | Univ Aarhus | CIRCULAR RNA FOR INHIBITING MICRO-RNA |
| EP3234134B1 (en) * | 2014-12-17 | 2020-05-27 | ProQR Therapeutics II B.V. | Targeted rna editing |
| WO2017220751A1 (en) * | 2016-06-22 | 2017-12-28 | Proqr Therapeutics Ii B.V. | Single-stranded rna-editing oligonucleotides |
| WO2018237372A1 (en) * | 2017-06-23 | 2018-12-27 | Cornell University | RNA MOLECULES, METHODS FOR PRODUCING CIRCULAR RNA, AND METHODS OF TREATMENT |
| US20220010333A1 (en) * | 2018-09-06 | 2022-01-13 | The Regents Of The University Of California | Rna and dna base editing via engineered adar recruitment |
| EP3997229A4 (en) * | 2019-07-12 | 2024-07-03 | Peking University | TARGETED RNA EDITING BY HARNESSING ENDOGENOUS ADAR USING MODIFIED RNA |
| WO2021113264A1 (en) * | 2019-12-02 | 2021-06-10 | The Regents Of The University Of California | Engineering circular guide rnas |
-
2021
- 2021-05-26 JP JP2022573508A patent/JP2023528039A/ja active Pending
- 2021-05-26 EP EP21733641.1A patent/EP4158017A1/en not_active Withdrawn
- 2021-05-26 US US17/998,322 patent/US20230174977A1/en active Pending
- 2021-05-26 WO PCT/US2021/034301 patent/WO2021242889A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023528039A5 (https=) | ||
| Qiao et al. | Liver-specific microRNA-122 target sequences incorporated in AAV vectors efficiently inhibits transgene expression in the liver | |
| US8053232B2 (en) | Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated RNA trans splicing | |
| CN109072235B (zh) | 通过核递送crispr/cas9追踪并操纵细胞rna | |
| JP2023527354A5 (https=) | ||
| EP3129485B1 (en) | Crispr/cas-related methods and compositions for treating cystic fibrosis | |
| AU2017379073B2 (en) | Compositions and methods for treating alpha-1 antitrypsin deficiency | |
| Moshiri et al. | Inhibiting the oncogenic mir-221 by microRNA sponge: toward microRNA-based therapeutics for hepatocellular carcinoma | |
| CN103290009B (zh) | 具有促进iNOS mRNA的分解的NO产生抑制活性的正义寡核苷酸以及iNOS产生量的抑制方法 | |
| JP2021511047A5 (https=) | ||
| CN112930395A (zh) | 靶向rna的融合蛋白组合物和使用方法 | |
| WO2023165009A1 (zh) | 一种用于制备环状rna的载体及其应用 | |
| JP2022505381A5 (https=) | ||
| JP2005501557A5 (https=) | ||
| IL292999A (en) | Compositions and methods of treating amyotrophic lateral sclerosis (als) | |
| Valdmanis et al. | RNA interference–induced hepatotoxicity results from loss of the first synthesized isoform of microRNA-122 in mice | |
| BR112016023004B1 (pt) | Sirna, estrutura oligo rna de fita dupla, nanopartícula, composição farmacêutica e estrutura liofilizada para prevenir ou tratar fibrose ou doenças respiratórias contendo a mesma | |
| WO2019196887A1 (zh) | 一种新型小激活rna | |
| JP2024543782A (ja) | Ｃａｇリピート疾患を治療するための組成物および方法 | |
| Mendoza et al. | Structural and functional effects of inosine modification in mRNA | |
| JP2022534627A (ja) | Ｄｍｐｋ遺伝子を標的とした筋ジストロフィーの治療方法 | |
| Garcia-Guerra et al. | Tissue-specific modulation of CRISPR activity by miRNA-sensing guide RNAs | |
| CN113584027B (zh) | 一种激活p21基因表达的方法 | |
| JP2022522166A5 (https=) | ||
| CA3216909A1 (en) | Viral vector compositions and methods of use thereof |